본문 바로가기
logo
메뉴
COMPANY
About the Company
CEO’s Message
History
R&D Team
Direction
R&D
Pipeline
PINOT-ADC™
NTX-301
NTX-101
Business Performance
IR
Public Notice
PR
Notification
Press Release
Media Coverage
HOME
CONTACT
ENG
KOR
Leading
Global Biotech,
Pinotbio
COMPANY
About the Company
CEO’s Message
History
R&D Team
Direction
R&D
Pipeline
PINOT-ADC™
NTX-301
NTX-101
Business Performance
IR
Public Notice
PR
Notification
Press Release
Media Coverage
PR
Accuracy with expediency
Media Coverage
HOME
PR
Media Coverage
2023
05.10
Pinotbio seeks preliminary review of listing on Kosdaq
2023
01.26
Bridge Biotherapeutics, Pinotbio join hands to develop cancer therapeutics using ADCs
2023
01.04
Korean biopharma firms actively develop ADC drugs through ‘open innovation’
2022
12.20
Six start-ups win Innovation Start-up Korea Awards
2022
10.21
Celltrion bulks out ADC ambition with Pinotbio tech deal
2022
08.23
ADCs Are The Future Of Precision Chemotherapeutics
2022
07.13
Aptamer Group and PinotBio Extend Collaboration Agreement
2022
06.19
Birmingham organization advancing cancer treatment research
2021
06.02
Aptamer Group and PinotBio collaborate to develop new therapeutic drug conjugates
1